Skip to content
You are now leaving to visit

Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA

CARLSBAD, Calif. , Nov. 6, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the company submitted a new drug application (NDA) to the U.S. Food and Drug Administration for inotersen, an investigational medicine for the treatment of patients with hereditary TTR